|
| Hans BarellaHans Barella, President of the Supervisory Board of SuperSonic Imagine, was previously President and Chief Executive Officer of Philips Medical Systems and member of the Group Management Committee of Royal Philips Electronics. Hans Barella has, for the past 30 years, occupied several key positions at Philips Medical Systems, including commercial, marketing and technical roles. He became member of the top management team in 1985 and was appointed President and CEO of Philips Medical Systems in 1997. In this role, he initiated an ambitious acquisition program and consolidated five major companies into one organization dedicated to diagnostics, treatment and patient monitoring. Additionally, from 1992 to 1996, he was Chairman of COCIR: the European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry. Hans Barella has been a member of the Board of Directors of Elekta AB, Sweden since 2003. Mr. Barella has a Masters of Business Administration (MBA) and an Electronic Engineering degree.
|
|
| Philippe BoucheronPhilippe Boucheron holds an engineering degree in Biochemical Engineering and Microbial genetics from the Institut National des Sciences Appliquées in Toulouse, a MSc in Biochemical Engineering from the Ecole Polytechnique of Montreal, and a MBA from INSEAD. Between 1993 and 1996, Philippe Boucheron worked at BioCapital LP, one of the largest Canadian venture capital funds, focusing on biotechnology. From 1997 to 2000, he directed the mid-caps equity research team at ING Barings Ferri, Paris. Here, he spent a significant part of his time following French and European biotech companies. In 2000, he co-founded Bioam and became the Investment Manager, then a Managing Partner in 2004. He sits on the boards of Aureus Pharma, Libragen, Ademtech, Integragen, Cryolog, SSI and TxCell. After the merger of Bioam with CDC entreprises in July 2010, Philippe Boucheron joined the direct investment in life sciences team of CDC entreprises.
|
|
| Aris ConstantinidesAris Constantinides is the founder and Investment Director of London-based NBGI Ventures, one of the few European venture capital firms investing exclusively in medical technology companies. Aris currently serves on the boards of a number of medtech companies including: 2010 Perfect Vision, Endoscopic Technologies, EOS Imaging, Forth Photonics Limited, Reverse Medical and SuperSonic Imagine.
Aris started his career at Bankers Trust where he was a structurer of innovative derivative products. He has more than 14 years of experience with European venture capital and private equity, including Deutsche Bank’s and Credit Suisse First Boston’s funds.
He holds Mechanical Engineering degrees from Imperial College and MIT an MBA from Insead.
|
|
| Olivier LitzkaOlivier Litzka joined Edmond de Rothschild Investment Partners’ (EdRIP) as a partner in 2006. He invests in Biotechnology and Medtech companies mainly in Europe, but also selectively in the US. Olivier serves on the boards of Noxxon Pharma (Berlin), Endosense (Geneva), JenaValve (Munich), and Probiodrug (Halle), as well as SuperSonic Imagine. Up until its acquisition by AstraZeneca, he was also a member of the board of Novexel (France). Before joining EdRIP, Olivier spent six years with 3i’s life science venture capital practice, based first in Munich and then in Paris. In this position, he served on the boards of several portfolio companies and made a range of international investments. Before joining 3i in 2000, he worked as a strategy consultant with Mercer Management Consulting, both in Munich and Paris. Olivier holds a PhD in molecular microbiology from the Institut für Mikrobiologie at the University of Munich and performed his scientific research work over several years in Munich and Oxford.
|
|
| Bernard DaugerasCo-founder Chairman of the Board of Auriga Partners, Bernard is an expert in Life Sciences and was behind successful investments such as BioAlliance Pharma (EuroNext : BIO), NicOx (EuroNext : COX). He is a member of the French Academy of Technologies. Bernard began his career doing research into particle physics at the University of Orsay, the University of California at Berkeley, and CNRS, the French national scientific research center. He subsequently held senior posts at the French Ministry of Industry and Research, where he was in charge of promoting technology transfer from research institutions and of optimizing relations between Research and Industry. After 4 years in the Crédit Lyonnais setting up the bank's Venture Capital arm, he joined Finovelec in 1990. Bernard is a graduate of the Ecole Polytechnique and has a PhD from the University of Orsay.
|
|
| Alexia PerouseAlexia Perouse has a mix Neurosciences & Management of Enterprise background and joined the venture capital field in 1999. Partner at Omnes Capital, she invests in Life science and has developed the Medical Device portfolio.
Alexia Perouse has particularly followed the companies Biolipox (merged with Orexo in 2007) and Mutabilis (sold to Pharma Omnium International in 2009).
She has invested in Fovea Pharmaceuticals (sold to Sanofi Aventis in 2009). In addition of her investment in SuperSonic Imagine since the Serie A, she has developed the Medtech portfolio through numerous investments in Cellnovo, CircuLite, Eos Imaging, EyeTechCare, SpineGuard and Stentys (IPO in 2010). She currently sits at 6 boards. Before joining the venture capital within Sofinnova Partners and then CAPE in 2005, Alexia Perouse has carried out missions of consulting & business development at Parteurop Développement for biotech start-ups. She started her career as an analyst at Chiron Vaccines.
|
|
| Paul-Louis SantyPaul-Louis Santy has over 25 years of private equity experience, including 19 years as founding CEO of Sudinnova, a French venture capital fund launched with Sofinnova, then at Siparex, one of the leading french private equity firms, as head of Venture Capital and member of Siparex group management board. His track record in life sciences investments includes Seporga, Genset, Biomatech, Coletica and Flamel Technologies. Paul-Louis has also invested in software and electronics segments. He has been a board member of the Association Française des Investisseurs en Capital (A.F.I.C.), formerly worked for Veolia Group. Paul-Louis is a graduate of I.E.P. de Paris (Sciences Po.) and holds a Master in Economics.
|
|
| Jean-Michel Petit(Observer) Jean-Michel Petit has been the investment director at Ixo private equity since 2003. Jean-Michele began his career in Research & Development for Sumitomo Rubber Industries. After a move to Canada, he joined Innovatech du Grand Montreal and later CDP Capital where he was actively involved in capital investment projects for companies in Europe, USA and Canada. He joined ICSO Private Equity in 2003. Jean-Michele Petit is a graduate in chemistry from the Ecole National Supérieure de Chimie de Paris. He also holds an MBA in Buisness Administration from McGill University, Montreal.
|
|
| Erich Schlick(Observer) Erich Schlick is one of a very few European scientists to see their innovation become a huge sucess, when, in the 1990s, he initiated the development of Humira, the first fully human therapeutic mononucleosis antibody. Erich Schlick joined Wellington as an Investment Partner for Life Sciences in October 2005. Before this, he served as Director and Head of 3i Healthcare, Germany and as Deputy Sector Head of 3i Healthcare Worldwide. He was responsible for numerous successful investments. Prior to working in the venture capital industry, Erich spent 15 years with BASF Pharma Knoll AG, including 10 years as an executive board member with worldwide responsibility for preclinical and clinical R&D. He also obtained worldwide patents for five products in cardiovascular, metabolic and pain releif. In 1993, he established a partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira. Erich Schlick studied medicine and specialised in pharmacology. He holds a professorship of immunopharmacology at the University of Heidelberg/Mannheim.
|
|
| Takashi Mori(Observer) Takashi Mori is Chief of Canon Inc.’s Medical Imaging Project within the company’s Corporate R&D Headquarters, and is leading initiatives to grow Canon’s Healthcare business through innovations based on Canon’s cutting-edge technologies. Prior to joining Canon in 2009, he spent 15 years at General Electric Company in Japan in various management positions, including Executive Director, Strategic Growth at GE Healthcare’s Medical Diagnostic Business, and Executive Vice President & Director at Nihon Medi-Physics Co., a joint venture between GE and Sumitomo Chemical Co. Ltd. Mr. Mori earned a BS in Material Physics in Japan from Osaka University, Osaka, and an MBA in the United States from Anderson Graduate School of Management at UCLA, Los Angeles, California.
|
